Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma

NCT03786237 is registered in ClinicalTrials.gov with Prof. Johann Bauer as lead sponsor.

NCT NCT03786237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03786237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Study to Assess Efficacy and Safety of Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated Locally Advanced/Metastatic Squamous Cell Carcinoma
Lead sponsor
Prof. Johann Bauer
Phase
Phase 1/2
Overall status
Completed
Start date
April 12, 2021
Completion date
December 1, 2025
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epidermolysis bullosa dystrophica, squamous cell carcinoma